Clinical Trial: The First-in-Human Study of GW906 Injection

U.S., Oct. 21 -- ClinicalTrials.gov registry received information related to the study (NCT07884461) titled 'The First-in-Human Study of GW906 Injection' on Sept. 17.

Brief Summary: This study is a randomized, double-blind, placebo-controlled, single-dose, dose-escalation trial to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of GW906 in healthy subjects and subjects with mild hypertension, as well as to conduct an initial exploration of its clinical efficacy.

Study Start Date: March 29, 2025

Study Type: INTERVENTIONAL

Condition: Hypertension

Intervention: DRUG: GW906 injection

GW906 injection

DRUG: Placebo

Normal saline

Recruitment Status: COMPLETED

Sponsor: Shenzhen Salubris Pharmaceuticals Co., Ltd...